We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





CerTest Demonstrates VIASURE Real Time PCR Complete Solution at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023

CerTest Biotec (Zaragoza, Spain) is presenting several novel products for research and diagnosis at Medlab Middle East 2023, including its VIASURE Real Time PCR Complete Solution, along with equipment and reagents for CLIA. More...

The VIASURE Complete Solution comprises the VIASURE RNA/DNA extraction kits, the V-FLEX nucleic acid extraction and PCR set-up system, V-Lab96 Real Time PCR system and V-Smart automatic interpretation software.

The VIASURE V-FLEX system is a fully automated solution in molecular biology for nucleic acid extraction, purification and PCR set-up from biological matrix and samples. The instrument has been designed with flexible configuration, in order to meet different user needs. The VIASURE V-Lab96 Advanced Real Time PCR System with 96-well block for high sample throughput in diagnostic lab applications. VIASURE V-Lab96 allows users to analyze 96 samples simultaneously for qualitative and quantitative PCR. The VIASURE V-Smart software for the analysis and interpretation of VIASURE RT PCR assays facilitates the conversion of the PCR raw data into test results with minimal manual intervention. Additionally, VIASURE Real Time PCR Detection Kits allow for simultaneous detection of multiple targets in a broad range of multiplexing diagnostic panels, including in the area of antimicrobial resistance.

Recently, CerTest had announced that the company will run its campaign ‘More than Diagnostics’ throughout 2023 in acknowledgement of the transformation that it has gone through, accelerated by the COVID-19 pandemic. CerTest’s ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future, with people’s health remaining its key focus.

Related Links:
CerTest Biotec


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Aspiration System
VACUSAFE
New
Electrolyte Analyzer
BKE-B
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.